Ozempic Faces Wave Of Lawsuits As Claims Top $2 Billion
Updated on
Published on
- Roughly 2,000 plus GLP-1 injury suits, including Ozempic, are centralized in MDL No. 3094 in the Eastern District of Pennsylvania.
- Multiple outlets say combined claims could top $2 billion, driven by allegations of gastroparesis and vision loss; there is no single $2B case.
- Novo Nordisk disputes the allegations and also filed new U.S. lawsuits against sellers of compounded semaglutide.
- Case management orders and monthly status conferences continue as the MDL advances toward expert and discovery milestones.
Plaintiffs’ claims tied to Ozempic and other GLP-1 medicines have been consolidated in MDL 3094 in Philadelphia, where U.S. District Judge Karen Marston is holding regular status conferences and issuing case management orders that set the discovery and motion schedule. The MDL groups suits alleging gastrointestinal injuries such as gastroparesis and ileus, as well as related claims about warnings and marketing. Defendants Novo Nordisk and Eli Lilly deny that their products are defective or that warnings were inadequate.
Several business outlets now estimate that aggregate claims could exceed $2 billion, reflecting both the volume of filings and the severity categories alleged by plaintiffs. Those estimates describe the potential combined exposure across many suits rather than a single blockbuster complaint, and they will ultimately depend on court rulings, expert testimony, and any bellwether outcomes or settlements. Reported counts suggest the docket has grown past two thousand cases this summer, though tallies vary by source as filings continue.
Outside the MDL, Novo Nordisk has pursued its own litigation campaign against pharmacies and telehealth firms selling compounded versions of semaglutide. That separate push underscores how the legal landscape now spans both product liability claims and brand protection efforts around copycat supply. For patients and prescribers, the FDA and courts will remain central as evidence develops and as the MDL moves through expert disputes that are likely to shape what does or does not reach juries.
